Novartis AG stock (CH0012005267): eye drug approval and pipeline focus after first-quarter update

Novartis AG has secured a key US approval for its eye drug Beovu in a new use and recently reported first-quarter 2026 results, keeping attention on its innovative medicines pipeline and margin targets. What does this mean for the pharma heavyweight’s stock story?

Novartis AG has been back in the headlines in recent weeks after the US Food and Drug Administration (FDA) cleared its eye drug Beovu for treating diabetic macular edema and the Swiss pharma group presented its first-quarter 2026 results, underlining a continued focus on innovative medicines, productivity and shareholder returns, according to company statements and regulatory filings published in April and May 2026.Novartis newsroom as of 04/2026

As of: 20.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novartis
• Sector/industry: Pharmaceuticals, biotech
• Headquarters/country: Basel, Switzerland
• Core markets: Global prescription medicines, including the US and Europe
• Key revenue drivers: Innovative medicines in oncology, immunology, cardiovascular and neuroscience
• Home exchange/listing venue: SIX Swiss Exchange, New York Stock Exchange (ticker: NVS)
• Trading currency: Swiss franc on SIX, US dollar on NYSE

Novartis AG: core business model

Novartis AG is one of the world’s largest pharmaceutical groups, focused on researching, developing and marketing prescription medicines for serious chronic and acute diseases. The company has increasingly concentrated on innovative patented drugs and divested non-core assets over the past years, including the spin-off of its generics arm Sandoz, to sharpen its profile as a pure-play innovative medicines business, according to company strategy updates and past investor presentations released between 2022 and 2024.Novartis investors as of 10/2023

The business is structured mainly around therapeutic areas rather than older primary-care models. Novartis concentrates resources on oncology, immunology, cardiovascular, neuroscience and ophthalmology, where unmet medical needs and pricing power can support attractive margins and long patent lifecycles. This specialization requires high research and development (R&D) spending, but also allows the group to leverage scientific platforms such as gene therapy, cell therapy and targeted small molecules across multiple indications.

In addition to R&D, Novartis emphasizes large-scale, data-driven commercial operations in major markets such as the United States, the European Union and Japan. These operations help launch new products quickly and expand indications for existing medicines. The company seeks to balance investment in breakthrough therapies with disciplined cost control, aiming for mid- to high-twenties core operating margins over the medium term, as repeatedly stated in capital markets communications in 2023 and 2024.

Main revenue and product drivers for Novartis AG

Novartis generates the bulk of its revenue from a portfolio of blockbuster and near-blockbuster medicines in complex disease areas. In oncology, products such as Kisqali for breast cancer and Pluvicto for prostate cancer have been key growth engines in recent quarters, benefiting from label expansions and increasing physician adoption, according to the company’s quarterly updates and product briefings from 2024 and early 2025.Novartis media releases as of 02/2025

Cardiovascular and metabolic therapies also play an important role. Entresto, a heart-failure medicine, has been a cornerstone product for several years, and newer assets targeting cholesterol management and lipoprotein(a) are aimed at expanding the company’s footprint in this high-burden disease category. In neuroscience, treatments for multiple sclerosis and migraine have contributed to diversified revenue streams, though competition and patent expiries require constant innovation to sustain growth.

Ophthalmology, including the retina segment, is another focus area. The FDA’s recent approval of Beovu for diabetic macular edema added a new indication in a large patient population that often requires ongoing treatment to preserve vision, according to an approval notice and associated company communication released in April 2026.Novartis media release as of 04/2026 This label expansion could extend the lifecycle of the drug and broaden Novartis’s retina portfolio, although safety perceptions and competition from other anti-VEGF agents remain important factors.

From a geographic perspective, the United States is a crucial market for Novartis due to its size, pricing structures and openness to innovation. Revenue from the US contributes a substantial share of the company’s total sales, reflecting the importance of US regulators, payers and physicians in determining the commercial success of key medicines. For US investors, Novartis’s exposure to the American healthcare system means that changes in US drug-pricing rules, Medicare negotiations or oncology reimbursement can have a direct impact on earnings and valuation.

Why Novartis AG matters for US investors

Novartis AG is listed not only on the SIX Swiss Exchange but also on the New York Stock Exchange under the ticker NVS, making the stock directly accessible to US investors through American depositary receipts. The company’s strong presence in the US prescription drug market, particularly in oncology and cardiovascular medicine, means that its growth is closely tied to demand and reimbursement conditions in the United States.NYSE as of 05/2026

For investors in the US, Novartis can serve as a way to gain exposure to global pharma innovation while still trading on a domestic exchange in US dollars. The group’s dividend track record and share buyback programs have also been of interest to income-oriented investors, although dividend levels and capital return plans can change in response to pipeline investments, acquisitions or regulatory developments. Currency movements between the Swiss franc and the US dollar may additionally influence the dollar value of distributions.

Another aspect that may attract US investors is Novartis’s diversified pipeline, which includes advanced therapies such as gene and radioligand treatments that are being tested in US and global trials. Success or setbacks in these programs can lead to pronounced share-price movements on the NYSE, making clinical and regulatory milestones key catalysts to watch from a US market perspective. At the same time, growing scrutiny of drug prices in the US introduces a policy risk that could affect the company’s long-term profitability.

Conclusion

Novartis AG remains a major global pharma group with a sharpened focus on innovative prescription medicines, supported by high R&D spending and a broad late-stage pipeline. Recent developments such as the FDA approval of Beovu in diabetic macular edema and the publication of first-quarter 2026 results highlight both the opportunities and execution challenges inherent in specialty therapeutics. For US investors, the NYSE-listed shares offer exposure to a Swiss-based healthcare leader that is deeply integrated into the American drug market, but they also come with typical sector risks, including regulatory shifts, patent cliffs and clinical trial uncertainty. As always, individual decisions should weigh the company’s product strengths, pipeline prospects and financial profile against personal risk tolerance and investment horizons.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.